Loading organizations...
§ Private Profile · Liège, Liege, Belgium
Biotechnology company developing scalable, GMP-compliant exosome therapies from MSCs for rare diseases and bronchopulmonary dysplasia.
Based in Liège, Belgium, EXO Biologics is a clinical-stage biotechnology company that develops scalable, GMP-compliant exosome therapies derived from mesenchymal stem cells to address rare diseases and high unmet medical needs. The organization focuses on the large-scale manufacturing of extracellular vesicles for cell-free treatments, operating an integrated platform for clinical research, drug development, and commercial production. In December 2023, the enterprise initiated a Phase 2 clinical trial evaluating its allogeneic umbilical cord-derived therapies for bronchopulmonary dysplasia. Led by Chief Executive Officer Hugues Wallemacq and Chief Scientific Officer Marcin Jurga, the firm combines direct drug development with a licensing model executed through its sister company, ExoXpert. The company has also established strategic partnerships to accelerate its pipeline, including a collaboration with the American biotechnology firm NeuCore Bio. EXO Biologics was originally founded in the year 2019.
EXO Biologics has raised $17.1M across 1 funding round.
EXO Biologics has raised $17.1M in total across 1 funding round.
EXO Biologics has raised $17.1M across 1 funding round. Most recently, it raised $17.1M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 26, 2024 | $17.1M Series A | — | Belgian Family Offices, Founders, Noshaq, Walloon Region | Announced |
EXO Biologics has raised $17.1M in total across 1 funding round.
EXO Biologics's investors include Belgian family offices, Founders, Noshaq, Walloon Region.